Vibativ is a brand name of telavancin, approved by the FDA in the following formulation(s):
VIBATIV (telavancin hydrochloride - powder; iv (infusion))
Manufacturer: THERAVANCE INC
Approval date: September 11, 2009
Strength(s): EQ 250MG BASE/VIAL, EQ 750MG BASE/VIAL [RLD]
Has a generic version of Vibativ been approved?
No. There is currently no therapeutically equivalent version of Vibativ available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vibativ. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Glycopeptide phosphonate derivatives
Patent 6,635,618
Issued: October 21, 2003
Inventor(s): Michael R.; Leadbetter & Martin S.; Linsell
Assignee(s): Theravance, Inc.
Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.Patent expiration dates:
- September 22, 2021✓✓✓
- September 22, 2021
Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Patent 6,858,584
Issued: February 22, 2005
Inventor(s): Judice; J. Kevin & Shaw; Jeng-Pyng & Mu; YongQi & Conner; Michael W. & Pace; John L.
Assignee(s): Theravance, Inc.
Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.Patent expiration dates:
- August 24, 2022✓
- August 24, 2022
Glycopeptide phosphonate derivatives
Patent 6,872,701
Issued: March 29, 2005
Inventor(s): Leadbetter; Michael R. & Linsell; Martin S.
Assignee(s): Theravance, Inc.
Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.Patent expiration dates:
- June 5, 2021✓
- June 5, 2021
Glycopeptide phosphonate derivatives
Patent 7,008,923
Issued: March 7, 2006
Inventor(s): Leadbetter; Michael R. & Linsell; Martin S.
Assignee(s): Theravance, Inc.
Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.Patent expiration dates:
- May 6, 2021✓
- May 6, 2021
Glycopeptide phosphonate derivatives
Patent 7,208,471
Issued: April 24, 2007
Inventor(s): Leadbetter; Michael R.
Assignee(s): Theravance, Inc.
Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.Patent expiration dates:
- May 1, 2021✓✓
- May 1, 2021
Glycopeptide phosphonate derivatives
Patent 7,351,691
Issued: April 1, 2008
Inventor(s): Leadbetter; Michael R. & Linsell; Martin S.
Assignee(s): Theravance, Inc.
Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.Patent expiration dates:
- May 1, 2021✓✓✓
- May 1, 2021
Hydrochloride salts of a glycopeptide phosphonate derivative
Patent 7,531,623
Issued: May 12, 2009
Inventor(s): Liu; Jyanwei & Lee; Junning
Assignee(s): Theravance, Inc.
Disclosed are hydrochloride salts of telavancin having a chloride ion content of from about 2.4 wt. % to about 4.8 wt. %. The disclosed salts have improved stability during storage at ambient temperatures compared to other hydrochloride salts. Also disclosed are processes for preparing such salts.Patent expiration dates:
- January 1, 2027✓
- January 1, 2027
Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Patent 7,544,364
Issued: June 9, 2009
Inventor(s): Judice; J. Kevin & Shaw; Jeng-Pyng & Mu; YongQi & Conner; Michael W. & Pace; John L.
Assignee(s): Theravance, Inc.
Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.Patent expiration dates:
- May 1, 2021✓
- May 1, 2021
Glycopeptide phosphonate derivatives
Patent 7,700,550
Issued: April 20, 2010
Inventor(s): Leadbetter; Michael R.
Assignee(s): Theravance, Inc.
Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.Patent expiration dates:
- May 1, 2021✓
- May 1, 2021
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- September 11, 2014 - NEW CHEMICAL ENTITY
See also...
- Vibativ Consumer Information (Drugs.com)
- Vibativ Consumer Information (Wolters Kluwer)
- Vibativ Consumer Information (Cerner Multum)
- Vibativ Advanced Consumer Information (Micromedex)
- Vibativ AHFS DI Monographs (ASHP)
- Telavancin Consumer Information (Wolters Kluwer)
- Telavancin Consumer Information (Cerner Multum)
- Telavancin Intravenous Advanced Consumer Information (Micromedex)
- Telavancin Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment